Hemispherx advances flu vaccine trials

By Elaine Rigoli

Tampa, Fla., June 12 - Hemispherx Biopharma, Inc. has completed the final design of a well-controlled Ampligen versus placebo, immunopotentiation trial of seasonal influenza vaccinations.

The company said the design follows newly published Food and Drug Administration guidelines for determining potential efficacy.

The clinical study seeks to extend the findings from the preclinical models, including primates, being conducted in collaboration with the Japanese National Institute for Infectious Diseases, to determine the extent to which Ampligen may increase the effectiveness of vaccines and thereby broaden the availability of flu vaccine doses to treat more at-risk groups, such as senior citizens.

Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for the treatment of viral and immune-based disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.